Immune Checkpoint Inhibitors: all 7,814 studies that test it

Page 74 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT03178552Phase 2/3
• Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)Status unknownNCT03177239Phase 2
• PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal CancerTerminatedNCT03176264Phase 1
• Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain MetastasesActive, not recruitingNCT03175432Phase 2
• Avelumab and Cetuximab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer - The Phase II AVETUX-CRC Trial.CompletedNCT03174405Phase 2
• Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or LymphomasTerminatedNCT03172936Phase 1
• Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell CarcinomaActive, not recruitingNCT03172754Phase 1/2
• Neoantigen Reactive T Cells Combined With SHR-1210 for Chinese Patients With Advanced Refractory Solid TumorsStatus unknownNCT03171220Phase 1/2
• Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder CancerActive, not recruitingNCT03171025Phase 2
• Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsActive, not recruitingNCT03170960Phase 1
• Study of JS001 in Patients With Advanced Neuroendocrine TumorsCompletedNCT03167853Phase 1
• Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab and Standard of Care Chemotherapy in Squamous Non-Small Cell Lung Cancer and Extensive Stage Small Cell Lung CancerWithdrawnNCT03166254Phase 1
• Atezolizumab Combined with Immunogenic Chemotherapy in Patients with Metastatic Triple-negative Breast CancerCompletedNCT03164993Phase 2
• Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage III-IVB Head and Neck CancerCompletedNCT03162731Early Phase 1
• Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic MelanomaStatus unknownNCT03161756Phase 1/2
• UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC PatientsCompletedNCT03158883Early Phase 1
• NCT Neuro Master Match - N²M² (NOA-20)CompletedNCT03158389Phase 1/2
• Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell TumorsActive, not recruitingNCT03158064Phase 2
• Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)Active, not recruitingNCT03153202Phase 1/2
• A Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic MelanomaCompletedNCT03153085Phase 2
• Avelumab Plus Autologous Dendritic Cell Vaccine in Pre-treated Metastatic Colorectal Cancer PatientsCompletedNCT03152565Phase 1/2
• Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder CancerWithdrawnNCT03150836Phase 2
• Avelumab for MSI-H or POLE Mutated Metastatic Colorectal CancerStatus unknownNCT03150706Phase 2
• Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent NivolumabWithdrawnNCT03149159Phase 2
• Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue SarcomasWithdrawnNCT03149120Phase 2
• A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)Active, not recruitingNCT03148418Phase 3
• Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body RadiotherapyTerminatedNCT03148327Phase 1/2
• Phase II Study of Avelumab in Metastatic Gastronetro-pancreatic （GEP） Neuroendocrine Carcinoma （NEC, WHO Grade 3） as Second-line Treatment After Failing to Etoposide+Cisplatin: Integration of Genomic Analysis to Identify Predictive Molecular SubtypesCompletedNCT03147404Phase 2
• AssessinG Efficacy of Carboplatin and ATezOlizumab in Metastatic Lobular Breast CancerTerminatedNCT03147040Phase 2
• Nivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Stem Cell TransplantationStatus unknownNCT03146468Phase 2
• A Trial Using ctDNA Blood Tests to Detect Cancer Cells After Standard Treatment to Trigger Additional Treatment in Early Stage Triple Negative Breast Cancer PatientsStatus unknownNCT03145961Phase 2
• Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell CancerCompletedNCT03144778Phase 1
• A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver CancerCompletedNCT03143270Early Phase 1
• Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part SarcomaActive, not recruitingNCT03141684Phase 2
• Evaluation of Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated With Metronomic CyclophosphamideCompletedNCT03139851Phase 2
• Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCCCompletedNCT03136627Phase 1/2
• A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLCCompletedNCT03134872Phase 3
• Pembrolizumab for Metastatic NSCLC Patients Expressing PD-L1 Who Have Their Own PDXCompletedNCT03134456Phase 4
• Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)Active, not recruitingNCT03134118Phase 2
• A Trial to Evaluate Safety and Tolerability of SHR-1316 in Cancer PatientsCompletedNCT03133247Phase 1
• Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Either Pembrolizumab or Nivolumab TreatmentStatus unknownNCT03132675Phase 2
• Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and NeckCompletedNCT03132038Phase 2
• Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLCWithdrawnNCT03130764Phase 2
• Safety and Efficacy of Atezolizumab Combined to Preoperative Radio-chemotherapy in Localized Rectal CancerCompletedNCT03127007Phase 1/2
• Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian CancerCompletedNCT03126812Phase 1/2
• SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma PatientsWithdrawnNCT03126461Phase 2
• Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and NivolumabCompletedNCT03126331Phase 2
• Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast CancerActive, not recruitingNCT03125928Phase 2
• A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination ImmunotherapyActive, not recruitingNCT03122522Phase 2
• Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid CancerCompletedNCT03122496Phase 1
• A Study to Evaluate the Safety and Efficacy of SHR-1210, Gemcitabine and Cis-platinum by R/M NPC SubjectsCompletedNCT03121716Phase 1
• Nivolumab in Treating Patients With Advanced Metastatic Non-small Cell Lung CancerWithdrawnNCT03121417Phase 2
• A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid TumorsTerminatedNCT03119428Phase 1
• Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple MyelomaCompletedNCT03111992Phase 1
• Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell CancerWithdrawnNCT03111901Phase 1/2
• Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung CancerActive, not recruitingNCT03110978Phase 2
• Study of Pembrolizumab in Metastatic Biliary Tract Cancer as Second-line Treatment After Failing to at Least One Cytotoxic Chemotherapy Regimen: Integration of Genomic Analysis to Identify Predictive Molecular SubtypesCompletedNCT03110328Phase 2
• Treatment of Relapsed or Refractory Natural Killer/T Cell LymphomaStatus unknownNCT03107962Phase 2
• Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG ImmunotherapyTerminatedNCT03106610Phase 1
• Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic CancerActive, not recruitingNCT03104439Phase 2
• Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal CancerCompletedNCT03102047Phase 2
• Phase I Study of KN035 in Chinese Subjects With Advanced Solid TumorsCompletedNCT03101488Phase 1
• Synergism of Immunomodulation and Tumor AblationCompletedNCT03101475Phase 2
• A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast CancerCompletedNCT03101280Phase 1
• Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal OriginTerminatedNCT03100006Phase 1/2
• Pembrolizumab Plus Y90 Radioembolization in HCC SubjectsStatus unknownNCT03099564Early Phase 1
• A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid TumorsCompletedNCT03099109Phase 1
• Immunotherapy Study of Evofosfamide in Combination With IpilimumabStatus unknownNCT03098160Phase 1
• Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal CarcinomaActive, not recruitingNCT03097939Phase 2
• A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder CancerCompletedNCT03093922Phase 2
• A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the ExtremityActive, not recruitingNCT03092323Phase 2
• Study of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung CancerTerminatedNCT03091491Phase 2
• MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.CompletedNCT03089645Phase 1
• PDL-1 Targeting in Resectable Oesophageal CancerCompletedNCT03087864Phase 2
• A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLCStatus unknownNCT03085069Phase 2
• BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung CancerCompletedNCT03083691Phase 2
• Durvalumab Alone or With Tremelimumab in Refractory Germ Cell TumorsTerminatedNCT03081923Phase 2
• Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal CancerCompletedNCT03081494Phase 1
• A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based ChemotherapyActive, not recruitingNCT03076554Phase 2
• Atezolizumab and Bevacizumab in Treating Patients With Rare Solid TumorsActive, not recruitingNCT03074513Phase 2
• Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal MelanomaActive, not recruitingNCT03068624Phase 1
• Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDSCompletedNCT03066648Phase 1
• Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)CompletedNCT03063762Phase 1
• CheckpOiNt Blockade For Inhibition of Relapsed MesotheliomaCompletedNCT03063450Phase 3
• Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic SignatureActive, not recruitingNCT03061539Phase 2
• A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid TumorsCompletedNCT03059823Phase 1
• Immunotherapy as Second-line in Patient With Small Cell Lung CancerCompletedNCT03059667Phase 2
• Phase II Study of Durvalumab in Combination With Lenalidomide in Relapsed/Refractory NK-T-cell LymphomaStatus unknownNCT03054532Phase 2
• Adjuvant Pembrolizumab in N2 Positive Non-small Cell Lung Cancer PatientsStatus unknownNCT03053856Phase 2
• APL-501 Study for Select Advanced or Relapsed/Recurrent Solid TumorsCompletedNCT03053466Phase 1
• Durvalumab, Cetuximab and Radiotherapy in Head Neck CancerStatus unknownNCT03051906Phase 1/2
• A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of BCD-100 in Patients With Advanced Solid TumorsStatus unknownNCT03050047Phase 1
• Ipilimumab and Nivolumab in the Treatment of Malignant Pleural MesotheliomaCompletedNCT03048474Phase 2
• A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung CancerWithdrawnNCT03048136Phase 3
• Durvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Tract CancerActive, not recruitingNCT03046862Phase 2
• Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal CancerActive, not recruitingNCT03044613Phase 1
• Nivolumab in Prostate Cancer With DNA Repair Defects (ImmunoProst Trial)Status unknownNCT03040791Phase 2
• A Study of Durvalumab in Patients With BR PDA Following Neoadjuvant Therapy and Successful Surgical ResectionWithdrawnNCT03038477Phase 2
• Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell CarcinomaWithdrawnNCT03035630Phase 2
• A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)Active, not recruitingNCT03033914Phase 1/2

← Immune Checkpoint Inhibitors overview